Pharmacogenomic Testing for <i>CYP2C19</i> Variants among Stroke Patients Treated with Clopidogrel: Opportunity for the Clinical Laboratory?

Pharmacogenomic testing for CYP2C19 variants is more economically justified for laboratories that serve a population enriched with CYP2C19 LOF alleles, than populations exhibiting a lower allele frequency. Within a clinical laboratory offering testing, restricting testing to certain populations is not ethical.